Stock Price Prediction

QNTM stock is currently trading at $2.95, reflecting a bearish sentiment after a 14.5% drop in pre-market trading due to recent volatility. Bulls argue that the company's focus on innovative treatments for neurodegenerative disorders, particularly its lead compound Lucid-MS, positions it for long-term growth. Additionally, the successful $500,000 funding tranche supports its business development, potentially driving the stock higher if clinical milestones are achieved.

QNTM stock is currently bearish, trading at $2.95, down 14.5% in pre-market trading. The decline is attributed to ongoing legal issues, including a $700M lawsuit alleging market manipulation, which has eroded investor confidence. Additionally, the stock's significant drop from $460 in 2020 to its current level reflects weak fundamentals and market skepticism.